SIGN 142: Management of Osteoporosis and the Prevention of Fragility Fractures

Zusammenfassung

Management of osteoporosis and the prevention of fragility fractures A national clinical guideline First published March 2015 Revised June 2020 Revised January 2021 SIGN142 Key to evidence statements and recommendations Levels of evidence 1 ++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1 – Meta-analyses, systematic reviews, or RCTs with

Kerninformationen

R For ‘conditional’ recommendations on interventions that should be ‘considered’, the guideline development group is confident that the intervention will do more good than harm for most patients. The choice of intervention is therefore more likely to vary depending on a person’s values and prefere...

Management of osteoporosis and the prevention of fragility fractures. Edinburgh: SIGN; 2021. (SIGN publication no. 142). [January 2021]. Available from URL: http://www.sign.ac.uk This document is licensed under the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International Licence....

Management of osteoporosis and the prevention of fragility fractures. Edinburgh: SIGN; 2021. (SIGN publication no. 142). [January 2021]. Available from URL: http://www.sign.ac.uk This document is licensed under the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International Licence....

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen